Potential Risks of Large-Volume Intravenous Fluid Therapy by Bacteria, Endotoxins, Trace Elements, and Particulate Matter

  • F. K. Port


Continuous arteriovenous hemofiltration (CAVH) has become a well-established alternative to dialysis therapy for acute renal failure (ARF) due to the multiple major advantages related to CAVH as discussed elsewhere in this book. The continued poor patient survival despite better alimentation, cardiovascular stability, and other advantages is an unresolved problem with CAVH. Late unexpected fatal complications despite successful maintenance by CAVH occur frequently at a time when the patient appears to recover from multiple organ failure. This puzzling Observation was shared by all members of an international panel at a symposium on CAVH for ARF at the University of Michigan in March 1984. In search for possible explanations for these late complications this chapter will review potential problems related to large-volume i.v. fluid administration.


Multiple Organ Failure Rubber Particle United States Pharmacopeia Poor Patient Survival Substitution Fluid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Henderson LW, Beans E (1978) Successful production of sterile pyrogen free electrolyte Solution by ultrafiltration. Kidney Int 14: 522–525PubMedCrossRefGoogle Scholar
  2. 2.
    Shaldon S, Beau MC, Deschodt G, Flavier JL, Nilsson L, Ramperez P, Mion C (1983) Three years of experience with on-line preparation of sterile pyrogen free infusate for hemofiltration. Int J Artif Organs 6: 25–26PubMedGoogle Scholar
  3. 3.
    Felts SK, Schaffner W, Melly MA, Koenig MG (1972) Sepsis caused by contaminated intravenous fluids. Ann Intern Med 77: 881–890PubMedGoogle Scholar
  4. 4.
    Maki DG, Rhame FS, Mackel DC, Bennett JV (1976) Nationwide epidemic of septicemia caused by contaminated intravenous products. I. Epidemiologie and clinical features. Am J Med 60: 471–485Google Scholar
  5. 5.
    Frei U, Koch KM (1983) Fever and shock during haemofiltration. Contrib Nephrol 36: 107–114PubMedGoogle Scholar
  6. 6.
    Port FK, Bernick JJ (1983) Pyrogen and endotoxin reactions during hemodialysis. Contrib Nephrol 36: 100–106PubMedGoogle Scholar
  7. 7.
    Duma RJ, Latta T (1976) What have we done - the hazards of intravenous therapy. N Engl J Med 294: 1178–1180PubMedCrossRefGoogle Scholar
  8. 8.
    D’Arcy PF, Woodside W (1973) Drug additives: a potential source of bacterial contamination of infusion fluids. Lancet 2: 96PubMedCrossRefGoogle Scholar
  9. 9.
    Kantor RJ, Carson LA, Graham DR, Petersen NJ, Favero MS (1983) Outbreak of pyrogenic reactions at a dialysis center. Am J Med 74: 449–456PubMedCrossRefGoogle Scholar
  10. 10.
    von Herrath D, Schaefer K, Hufler M, Pauls A, Koch KM, Göhl H, Ljunggren L, Gardiner P (1983) Complications of hemofiltration. Int J Artif Organs 6: 49–52Google Scholar
  11. 11.
    Kaehny WD, Hegg AP, Alfrey AC (1977) Gastrointestinal absorption of aluminum from aluminum-coating antacids. N Engl J Med 296: 1389–1390PubMedCrossRefGoogle Scholar
  12. 12.
    Kevy S, Jacobson M (1983) Hepatic effects of the leaching of phthalate ester plasticizer and Silicon. Contrib Nephrol 36: 82–89PubMedGoogle Scholar
  13. 13.
    Neergaard J, Nielsen B, Faubry V, Christensen DH, Nielson OF (1971) Plasticizers in PVC and the occurrence of hepatitis in a haemodialysis unit. Scand J Urol Nephrol 5: 141–145PubMedCrossRefGoogle Scholar
  14. 14.
    United States Pharmacopeia, 20th revision (1980) p 863Google Scholar
  15. 15.
    British Pharmacopeia (1980) Cambridge University Press, Cambridge, p 578Google Scholar
  16. 16.
    Turco SJ (1981) Hazards associated with parenteral therapy. Am J Therap Clin Nutr 8: 9–50Google Scholar
  17. 17.
    Blanchard J, Thompson CM, Schwartz JA (1976) Comparison of methods for detection of particulate matter in large-volume parenterals. Am J Hosp Pharm 33: 144–150PubMedGoogle Scholar
  18. 18.
    Bommer J, Waldherr R, Gastner M, Lemmes R, Ritz E (1981) Iatrogenic multiorgan silicone inclusions in dialysis patients. Klin Wochenschr 59: 1149–1157PubMedCrossRefGoogle Scholar
  19. 19.
    Leong ASA, Disney APS, Gove DW (1982) Spallation and migration of silicone from blood-pump tubing in patients on hemodialysis. N Engl J Med 306: 135–136PubMedCrossRefGoogle Scholar
  20. 20.
    DeLuca PP, Rapp RP, Bivins B, McKean HE, Griffen WO (1975) Filtration and infusion Phlebitis: a double-blind prospective clinical study. Am J Hosp Pharm 32: 1001–1007Google Scholar
  21. 21.
    Evans WE, Barker LF, Simone JV (1976) Double-blind evaluation of 5 Jim final filtration to reduce postinfusion phlebitis. Am J Hosp Pharm 33: 1160–1163PubMedGoogle Scholar
  22. 22.
    Dimmick JE, Bove KE, McAdams AJ, Benzing G III (1975) Fiber embolization–a hazard of cardiac surgery and catheterization. N Engl J Med 292: 685–687PubMedCrossRefGoogle Scholar
  23. 23.
    Gesler RM, Garvin PJ, Klamer B, Robinson RU, Thompson CR, Gibson WR, Wheeler FC, Carlson RG (1973) The biological effects of polystyrene latex particles administered intravenously to rats, a collaborative study. Bull Parenter Drug Assoc 27: 101–113PubMedGoogle Scholar
  24. 24.
    Brommer J, Waldherr R, Ritz E (1983) Silicone storage disease in long-term hemodialysis patients. Contrib Nephrol 36: 115–126Google Scholar
  25. 25.
    Anonymus (1975) I.V. filtere. Medical Letter 17: 35–36Google Scholar
  26. 26.
    Port FK, Bernstein IA (1981) Hepatitis risk from hemodialysis pressure monitors. An in vitro investigation. Artif Organs 5: 638–641Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1985

Authors and Affiliations

  • F. K. Port

There are no affiliations available

Personalised recommendations